Treatment of generalized vitiligo with anti-TNF-α agents

Journal of Drugs in Dermatology

Volumn 11, Issue 4, 2012, Pages 534-539

  AlGhamdi, Khalid M ^a   Khurrum, Huma ^a   Taïeb, Alain ^b   Ezzedine, Khaled ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b HÔPITAL PELLEGRIN   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; PIMECROLIMUS; STEROID; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PHOTOGRAPHY; PHOTOTHERAPY; PSORIASIS; RASH; SKIN PIGMENTATION; STEROID THERAPY; TREATMENT DURATION; TREATMENT FAILURE; VITILIGO;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO; YOUNG ADULT;

EID: 84859576824     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. E. Dogra A, Sachdeva S. Biologic therapy in psoriasis. Indian J Dermatol Venereol Leprol. 2006;72(4):256-264.
2. Kemp EH, Waterman EA, Weetman AP. Immunological pathomechanisms in vitiligo. Expert Rev Mol Med. 2001;3(20):1-22.
3. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, et al. Immunopathogenesis of Vitiligo. Autoimmun Rev. 2011 Feb 17. Epub ahead of print.
4. AlGhamdi KM, Huma K, Rikabi A. Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cut Med Surg. 2011 (In Press JMS-2011-10068)
5. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156(5):945-950. (Pubitemid 46642856)
6. Birol A, Kisa U, Kurtipek GS, et al. Increased tumor necrosis factor alpha (TNF-a) and interleukin 1-a (IL1-a) levels in the lesional skin of patients with non segmental vitiligo. Int J Dermatol. 2006;45(8):992-993. (Pubitemid 44145043)
7. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 2002; 15:87-89
8. Wong M, Ziring D, Korin Y, et al. TNF alpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126(2):121-136.
9. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51(1):52-61. (Pubitemid 38887475)
10. Lv Y, Li Q, Wang L, Gao T. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo. Med Hypotheses. 2009;72(5):546-7.
11. Simon JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology. 2008;216(3):234-235.
12. Berger TG, Klesewetter F. Psoriasis confines strictly to vitiligo areas- a Koebner like phenomenon? J Eur Acad Dermatol Venereol. 2006; 20:178-183.
13. Rigopoulos D, Gregoriou S, Larios G, et al. Etanercept in the treatment of vitiligo. Dermatology. 2007;215(1):84-85.
14. Shukla R, Vender RB. Pharmacology of TNF inhibitors. In: Weinberg JM, Buholtz R, editors. TNF-alpha Inhibitors. Basel: Birkhäuser Verlag; 2006:23-43.
15. European Medicines Agency. Summary of product characteristics. 3 April 2008. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ humira/H-481-PI-en.pdf.
16. Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol. 2008;58(2 Suppl):S50-S52.
17. Garcia-Valladares I, Cuchacovich R, Espinoza LR. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther. 2011;5:41-49.
18. Sharquie KE, Mehenna SH, Naji AA, Al-Azzawi H. Inflammatory changes in vitiligo: stage I and II depigmentation. Am J Dermatopathol. 2004;26(2):108-112. (Pubitemid 38429058)